河北医学
河北醫學
하북의학
HEBEI MEDICINE
2015年
1期
122-125
,共4页
急性脑梗死%依达拉奉%超敏C反应蛋白%肿瘤坏死因子-α%白细胞介素-8
急性腦梗死%依達拉奉%超敏C反應蛋白%腫瘤壞死因子-α%白細胞介素-8
급성뇌경사%의체랍봉%초민C반응단백%종류배사인자-α%백세포개소-8
Acute cerebral infarction%Edaravone%Hypersensitive C reactive protein%Tumor necrosis factor -α%Interleukin-8
目的：探讨依达拉奉对急性脑梗死患者血清炎性因子水平的影响，促进神经功能恢复，为临床合理用药提供理论依据。方法：选择符合标准的患者80例，随机分为观察组和对照组各40例，两组患者均给予综合治疗，观察组加用依达拉奉，比较二者血清超敏C反应蛋白（ hs－CRP ）、肿瘤坏死因子－α（ TNF－α）和白细胞介素－8（ IL－8）水平及神经功能变化。结果：入组时两组患者血清hs－CRP、TNF－α、IL－8水平相似，差异无统计学意义（ P＞0．05）；治疗7d、14d，两组患者血清hs－CRP、TNF－α、IL－8水平较治疗前均下降，但观察组患者的降低幅度更明显，差异比较有统计学意义（ P＜0．05）。观察组患者的神经功能恢复明显好于对照组，差异有统计学意义（ P＜0．05）。结论：依达拉奉能明显降低急性脑梗死患者的血清炎性因子水平，减轻炎性反应，减轻炎症反应和缺血再灌注损伤，促进神经功能恢复，临床疗效确切。
目的：探討依達拉奉對急性腦梗死患者血清炎性因子水平的影響，促進神經功能恢複，為臨床閤理用藥提供理論依據。方法：選擇符閤標準的患者80例，隨機分為觀察組和對照組各40例，兩組患者均給予綜閤治療，觀察組加用依達拉奉，比較二者血清超敏C反應蛋白（ hs－CRP ）、腫瘤壞死因子－α（ TNF－α）和白細胞介素－8（ IL－8）水平及神經功能變化。結果：入組時兩組患者血清hs－CRP、TNF－α、IL－8水平相似，差異無統計學意義（ P＞0．05）；治療7d、14d，兩組患者血清hs－CRP、TNF－α、IL－8水平較治療前均下降，但觀察組患者的降低幅度更明顯，差異比較有統計學意義（ P＜0．05）。觀察組患者的神經功能恢複明顯好于對照組，差異有統計學意義（ P＜0．05）。結論：依達拉奉能明顯降低急性腦梗死患者的血清炎性因子水平，減輕炎性反應，減輕炎癥反應和缺血再灌註損傷，促進神經功能恢複，臨床療效確切。
목적：탐토의체랍봉대급성뇌경사환자혈청염성인자수평적영향，촉진신경공능회복，위림상합리용약제공이론의거。방법：선택부합표준적환자80례，수궤분위관찰조화대조조각40례，량조환자균급여종합치료，관찰조가용의체랍봉，비교이자혈청초민C반응단백（ hs－CRP ）、종류배사인자－α（ TNF－α）화백세포개소－8（ IL－8）수평급신경공능변화。결과：입조시량조환자혈청hs－CRP、TNF－α、IL－8수평상사，차이무통계학의의（ P＞0．05）；치료7d、14d，량조환자혈청hs－CRP、TNF－α、IL－8수평교치료전균하강，단관찰조환자적강저폭도경명현，차이비교유통계학의의（ P＜0．05）。관찰조환자적신경공능회복명현호우대조조，차이유통계학의의（ P＜0．05）。결론：의체랍봉능명현강저급성뇌경사환자적혈청염성인자수평，감경염성반응，감경염증반응화결혈재관주손상，촉진신경공능회복，림상료효학절。
Objective:To investigate the effect of edaravone on the serum inflammatory factors in pa-tients with acute cerebral infarction , to promote the rehabilitation of nervous function , and to provide theoret-ic foundations for clinical reasonable medication .Method:80 eligible patients were selected and randomly divided into observation group and control group , 40 patients in each group;the patients of both groups were given with combined modality therapy , those of the observation group were additionally given with edaravone , and the changes in nervous function and serum hypersensitive C reactive protein ( hs-CRP ) , tumor necrosis factor -α( TNF-α) and interleukin-8 ( IL-8) levels between the patients of the two groups were compared . Result:When entering the groups , the serum hs-CRP , TNF-αand IL-8 levels in the patients of the two groups were similar , and the differences were statistically insignificant ( P>0.05);7 days and 14 days after the treatment , the serum hs-CRP , TNF-αand IL-8 levels in the patients of both groups were decreased when compared with those before the therapies , but the decreasing extents of the observation group were greater, and the differences were statistically significant (P<0.05).The rehabilitation of nervous function in the patients of the observation group was significantly better than that of the control group , and the difference was statistically significant (P<0.05).Conclusion: Edaravone can significantly decrease the serum inflam-matory factor levels, lighten the inflammatory reaction and ischemia-reperfusion injury, and promote the re-habilitation of nervous function in patients with acute cerebral infarction , and has positive clinical therapeutic effects.
